drugset / Trial / NCT00433576

Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery

NCT00433576

Phase 1 Completed 20 enrolled National Cancer Institute (NCI)
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of resveratrol in treating patients with colorectal cancer that can be removed by surgery. Resveratrol may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2006-12
Primary completion
2008-11
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Resveratrol Small molecule Oral